AUROBINDO

Date: July 11, 2018

| To | To |
|---|---|
| **NATIONAL STOCK EXCHANGE OF INDIA LIMITED**<br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br>**MUMBAI -400 051**<br><br>**Company Code No. AUROPHARMA** | **BSE LIMITED**<br>Phiroz Jeejeebhoy Towers,<br>25th floor, Dalal Street,<br>**MUMBAI -400 001**<br><br>**Company Code No. 524804** |

Dear Sirs,

**SUB: USFDA Approval for Azithromycin Tablets**

We enclose copy of the Press Release issued by the Company.

Please take the information on record.

Thanking you,

Yours faithfully,
**For AUROBINDO PHARMA LIMITED**

**B. Adi Reddy**
**Company Secretary**

NEWS RELEASE
11th July 2018, Hyderabad, India

**Aurobindo Pharma receives USFDA Approval for Azithromycin Tablets**

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Azithromycin tablets 250 mg and 500 mg. Azithromycin tablets are an AB-rated generic equivalent of Pfizer Inc's Zithromax tablets. The product will be launched in July 2018.

Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections. The approved product has an estimated market size of US$ 132 million for the twelve months ending May 2018 according to IQVIA.

This is the 146th ANDA (including 19 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 377 ANDA approvals (344 Final approvals including 17 from Aurolife Pharma LLC and 33 tentative approvals) from USFDA.

**About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

**For further information, please contact:**

Krishna Kiran
Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com

**Disclaimer:**

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch , implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.